1-6 of 6
Ruth Mary de Tute, PhD FRCPath
Close
Sort by
Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD
Journal: Blood
Blood (2016) 128 (22): 245.
https://doi.org/10.1182/blood.V128.22.245.245
Published: 2016
Journal Articles

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

Andy C Rawstron, BSc, PhD, Dena Howard, Lucy McParland, Ruth Mary de Tute, PhD FRCPath, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, PhD, Rebecca Bishop, BSc, Francesca J Yates, PhD MSci, Kristian Brock, MSc, BSc, Samuel Muñoz-Vicente, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 3226.
https://doi.org/10.1182/blood.V128.22.3226.3226
Published: 2016
Journal Articles

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Andy C Rawstron, BSc, PhD, Alex Smith, Ruth Mary de Tute, PhD FRCPath, Dan Painter, Eve Roman, Roger G Owen, MD
Journal: Blood
Blood (2016) 128 (22): 4451.
https://doi.org/10.1182/blood.V128.22.4451.4451
Published: 2016
Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong
Journal: Blood
Blood (2016) 128 (22): 4508.
https://doi.org/10.1182/blood.V128.22.4508.4508
Published: 2016
Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 2049.
https://doi.org/10.1182/blood.V128.22.2049.2049
Published: 2016
Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB
Journal: Blood
Blood (2015) 126 (23): 2669.
https://doi.org/10.1182/blood.V126.23.2669.2669
Published: 2015